ENDO HEALTH SOLUTIONS INC.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY13 | FY12 | FY11 | FY10 | FY09 | FY08 | |
|---|---|---|---|---|---|---|
| Revenue | $2.62B | $2.82B | $2.52B | $1.72B | $1.46B | $1.26B |
| Operating income | $21.7M | −$75.4M | $465.0M | $106.3M | $390.0M | $387.5M |
| Net income | $15.3M | −$87.3M | $187.6M | $60.4M | $266.3M | $255.3M |
| Total assets | $6.57B | $6.57B | $7.29B | $3.91B | $2.49B | — |
| Total liabilities | $3.34B | $3.06B | $3.54B | $1.13B | — | — |
| Equity | $526.0M | $1.07B | $1.98B | $1.74B | $1.50B | $1.21B |
| EPS (diluted) | $0.14 | $-0.75 | $1.55 | $2.20 | $2.27 | $2.06 |
| Shares out. | 111.0M | 116.7M | 117.3M | 116.1M | 117.3M | 123.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2013- Operating margin
- 0.8%
- Net margin
- 0.6%
- Return on equity
- 2.9%
- Return on assets
- 0.2%
- Return on capital (ROCE)
- 0.4%
- Liabilities / assets
- 50.8%
- Debt / equity
- 6.35×
- Book value / share
- $4.74
- Revenue growth (YoY)
- −7.1%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2013- Altman Z″ (distress)
- 1.41grey zone
- Accruals / assets
- −4.3%clean
- Beneish M-Score
- -2.66normal
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 warning● 3 good- Revenue declined year-over-year
- Altman Z″ in the grey zone
- Operating margin is positive
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Completed an acquisition or disposition · New financial obligation · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMar 3, 2014
- Results of operationsFeb 28, 2014
- Shareholder vote · Other material eventFeb 26, 2014
- Material impairment · Other material eventFeb 19, 2014
- Terminated a material agreement · Other material eventJan 21, 2014
- Entered a material agreement · Material impairmentJan 9, 2014
- Entered a material agreement · New financial obligationDec 19, 2013
- Other material eventDec 19, 2013
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- CT ORDERJun 18, 2019
- CT ORDERJan 27, 2017
- CT ORDERJul 5, 2016
- SC 13G/AENDP 12.31.14Feb 18, 2015
- SC 13G/AENDO HEALTH SOLUTIONS INC.Feb 17, 2015
- SC 13GFeb 11, 2015
- SC 13G/AApr 10, 2014
- CT ORDERMar 31, 2014
- 15-12BFORM 15Mar 10, 2014
- 4FORM 4 SUBMISSIONMar 3, 2014
- 4FORM 4 SUBMISSIONMar 3, 2014
- 4FORM 4 SUBMISSIONMar 3, 2014
- 4FORM 4 SUBMISSIONMar 3, 2014
- 4FORM 4 SUBMISSIONMar 3, 2014
- 4FORM 4 SUBMISSIONMar 3, 2014